Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 4/20 | 0.50 |
| ▸ | ADH1C | P00326 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17046171 | 0.97 | ADH1A (0.48) | ADH1AADH1CHRH4HRH3DRD2 | |
| SCHEMBL25510772 | 0.97 | ADH1A (0.52) | ADH1AADH1CHRH4HRH3DRD2 | |
| SCHEMBL5253027 | 0.97 | ADH1A (0.52) | ADH1AADH1CHRH4HRH3DRD2 | |
| SCHEMBL4754736 | 0.97 | — | — | |
| SCHEMBL8279455 | 0.97 | — | — | |
| SCHEMBL17046153 | 0.95 | ADH1A (0.50) | ADH1AADH1CHRH4HRH3DRD2 | |
| Hydrochloric Acid SCHEMBL5379324 | 0.95 | ADH1A (0.45) | ADH1AADH1CHRH4HRH3DRD2 | |
| SCHEMBL4756560 | 0.89 | — | — | |
| SCHEMBL95571 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL6609957 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-10294250-B2 | Organoaminosilanes and methods for making same | VERSUM MATERIALS US, LLC (US) | 2019-05-21 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170204120-A1 | Organoaminosilanes and Methods for Making Same | VERSUM MATERIALS US, LLC (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3039020-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| CN-103102303-B | As the benzyl amine derivative of CETP inhibitor | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-10-28 | — | — | CN | disclosed |
| WO-2015031295-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | WO | disclosed |
| CN-103102303-A | Benzylamine derivatives as CETP inhibitors | REDDY US THERAPEUTICS INC | 2013-05-15 | — | — | CN | disclosed |
| CN-101443006-B | Novel benzylamine derivatives as CETP inhibitors | REDDY US THERAPEUTICS INC | 2012-10-10 | — | — | CN | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| CN-101443006-A | Novel benzylamine derivatives as CETP inhibitors | REDDY US THERAPEUTICS INC (US) | 2009-05-27 | — | — | CN | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1599167-B1 | BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES HAVING AFFINITY FOR THE MELANOCORTIN RECEPTORS AND USE THEREOF AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204120-A1 | Organoaminosilanes and Methods for Making Same | DDAH1, IDUA, DDT | ADH1A 160/4885ADH1C 498/4885HRH4 753/4885 |
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | ADH1A 412/4885ADH1C 511/4885HRH4 1106/4885 |
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | ADH1A 3056/4885ADH1C 3227/4885HRH4 2556/4885 |
| US-10294250-B2 | Organoaminosilanes and methods for making same | DDAH1, IDUA, DDT | ADH1A 160/4885ADH1C 498/4885HRH4 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.